您的购物车当前为空
MYLS22 是视神经萎缩 1 的选择性抑制剂。它通过影响 NFkB 活性和血管生成基因表达抑制血管生成,靶向作用于内皮细胞 OPA1 ,减少肿瘤的生长。


为众多的药物研发团队赋能,
让新药发现更简单!
MYLS22 是视神经萎缩 1 的选择性抑制剂。它通过影响 NFkB 活性和血管生成基因表达抑制血管生成,靶向作用于内皮细胞 OPA1 ,减少肿瘤的生长。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 225 | In Stock | |
| 2 mg | ¥ 322 | In Stock | |
| 5 mg | ¥ 526 | In Stock | |
| 10 mg | ¥ 897 | In Stock | |
| 25 mg | ¥ 1,530 | In Stock | |
| 50 mg | ¥ 2,270 | In Stock | |
| 100 mg | ¥ 3,390 | In Stock | |
| 200 mg | ¥ 4,930 | In Stock | |
| 500 mg | ¥ 7,750 | In Stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 593 | In Stock |
| 产品描述 | MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity. |
| 体内活性 | MYLS22(10 mg/kg/天;肿瘤周围注射;每2天一次,连续14天)能够抑制小鼠的肿瘤生长。 |
| 分子量 | 443.52 |
| 分子式 | C24H21N5O2S |
| CAS No. | 306959-01-3 |
| Smiles | Cc1nn(-c2ccccc2)c2sc(cc12)C(=O)Nc1c(C)n(C)n(-c2ccccc2)c1=O |
| 密度 | no data available |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 45 mg/mL (101.46 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容